RGV005
AXP000139.1 · Oncolytic virus
- Platform
- vaccinia virus (in vivo CAR-delivering)
- Targets
- CD19
- Originator
- Second Affiliated Hospital, Zhejiang University School of Medicine
- Sponsor
- Second Affiliated Hospital, Zhejiang University School of Medicine
Names
| Name | Type | Source |
|---|---|---|
| RGV005 | preferred name, code | curator, ctgov |
| CD19-CAR novel oncolytic vaccinia virus | synonym | ctgov |
Virus
- Role
- Oncolytic
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Replication
- conditionally replicating
- Modifications
- oncolytic vaccinia encoding an anti-CD19 chimeric antigen receptor for in vivo CAR-T/CAR-macrophage generation
- Transgenes
- CAR (anti-CD19)
- Route
- intratumoral, intravenous
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07398963 | Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma | Recruiting | Phase 1 | 2026-02 | 2029-07 | 48 | Refractory/Relapsed B-cell Lymphoma |
Recent changes
No changes recorded in its trials yet.
Notes
Oncolytic vaccinia virus delivering an anti-CD19 CAR in vivo (CAR-T/CAR-macrophage), phase 1 NCT07398963 in relapsed/refractory B-cell lymphoma, intratumoral and intravenous arms, recruiting from February 2026. Distinct from CF33-CD19 (AXP000101), which instead makes tumour cells express truncated CD19: here the virus delivers the receptor to host immune cells. Strain and deletions not described.
How to cite
RGV005 (AXP000139.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000139.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.